Published in Curr Opin Immunol on November 03, 2012
Impact of the polymorphism in vitamin D receptor gene BsmI and the risk of systemic lupus erythematosus: an updated meta-analysis. Clin Rheumatol (2015) 1.42
Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011. PLoS One (2015) 1.40
T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? Arthritis Res Ther (2014) 1.34
Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat Immunol (2015) 1.20
Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell (2016) 0.93
The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol (2014) 0.92
Autoimmune effector memory T cells: the bad and the good. Immunol Res (2013) 0.91
Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis (2016) 0.87
Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol Med (2013) 0.85
Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun (2016) 0.84
Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev (2015) 0.84
Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis (2015) 0.83
Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy. Clin Rheumatol (2014) 0.83
Clinically mild encephalitis/encephalopathy with a reversible splenial lesion associated with febrile urinary tract infection. Eur J Pediatr (2013) 0.81
Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res Ther (2015) 0.80
Distribution of PTPN22 polymorphisms in SLE from western Mexico: correlation with mRNA expression and disease activity. Clin Exp Med (2015) 0.79
Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus. Arthritis Res Ther (2014) 0.79
K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis. Front Immunol (2016) 0.79
MicroRNA-let-7a promotes E2F-mediated cell proliferation and NFκB activation in vitro. Cell Mol Immunol (2013) 0.78
Patterns of foot complaints in systemic lupus erythematosus: a cross sectional survey. J Foot Ankle Res (2016) 0.77
Elevated Semaphorin5A in systemic lupus erythematosus is in association with disease activity and lupus nephritis. Clin Exp Immunol (2017) 0.77
The expression and clinical significance of different forms of Mer receptor tyrosine kinase in systemic lupus erythematosus. J Immunol Res (2014) 0.77
Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus. PLoS One (2015) 0.77
Vitamin D receptor gene BsmI polymorphisms in Egyptian children and adolescents with systemic lupus erythematosus: A case-control study. Medicine (Baltimore) (2016) 0.75
Alterations in nuclear structure promote lupus autoimmunity in a mouse model. Dis Model Mech (2016) 0.75
Association between killer cell immunoglobulin-like receptor (KIR) polymorphisms and systemic lupus erythematosus (SLE) in populations: A PRISMA-compliant meta-analysis. Medicine (Baltimore) (2017) 0.75
Prolactin Rescues Immature B-Cells from Apoptosis Induced by B-Cell Receptor Cross-Linking. J Immunol Res (2016) 0.75
Down-regulation of nectin-4 inhibits apoptosis in systemic lupus erythematous (SLE) through targeting Bcl-2/Bax pathway. Int J Clin Exp Pathol (2015) 0.75
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights (2016) 0.75
Association between Toll-Like Receptor 4 Polymorphisms and Systemic Lupus Erythematosus Susceptibility: A Meta-Analysis. Biomed Res Int (2016) 0.75
Elevated expression of TIGIT on CD3(+)CD4(+) T cells correlates with disease activity in systemic lupus erythematosus. Allergy Asthma Clin Immunol (2017) 0.75
CD16(+) Monocyte Subset Was Enriched and Functionally Exacerbated in Driving T-Cell Activation and B-Cell Response in Systemic Lupus Erythematosus. Front Immunol (2016) 0.75
Daphnetin inhibits inflammation in the NZB/W F1 systemic lupus erythematosus murine model via inhibition of NF-κB activity. Exp Ther Med (2016) 0.75
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. Br J Clin Pharmacol (2016) 0.75
Effects of royal jelly supplementation on regulatory T cells in children with SLE. Food Nutr Res (2016) 0.75
Categorisation of foot complaints in systemic lupus erythematosus (SLE) from a New Zealand cohort. J Foot Ankle Res (2017) 0.75
Increased serum sFas, sTRAIL, and reduced sFasL in juvenile-onset systemic lupus erythematosus. Clin Rheumatol (2017) 0.75
HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther (2017) 0.75
Dnase1L3 Regulates Inflammasome-Dependent Cytokine Secretion. Front Immunol (2017) 0.75
Plasma ficolin levels and risk of nephritis in Danish patients with systemic lupus erythematosus. Clin Rheumatol (2016) 0.75
MicroRNA 155-deficiency leads to decreased autoantibody levels and reduced severity of nephritis and pneumonitis in pristane-induced lupus. PLoS One (2017) 0.75
Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients. PLoS One (2017) 0.75
Neutrophil extracellular traps kill bacteria. Science (2004) 23.64
Follicular helper CD4 T cells (TFH). Annu Rev Immunol (2011) 12.50
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet (2011) 8.89
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science (2001) 8.14
Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity (2011) 5.98
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med (2011) 5.60
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
Follicular helper T cells: lineage and location. Immunity (2009) 4.75
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med (2011) 4.51
Follicular helper T cells are required for systemic autoimmunity. J Exp Med (2009) 4.25
Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science (2002) 4.21
Structure and function of anti-DNA autoantibodies derived from a single autoimmune mouse. Proc Natl Acad Sci U S A (1987) 3.90
Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science (2006) 3.84
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 3.83
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum (2011) 3.81
Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum (2010) 3.76
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med (1999) 3.74
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med (2003) 3.50
The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev (2003) 3.40
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med (2008) 3.39
Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nat Med (2010) 3.24
From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol (2001) 3.02
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med (2004) 2.85
The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol (2004) 2.67
In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol (2010) 2.63
Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum (2008) 2.63
The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med (1994) 2.61
Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest (2005) 2.55
A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci U S A (2009) 2.46
Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol (2009) 2.43
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature (2010) 2.31
Sites and stages of autoreactive B cell activation and regulation. Immunity (2008) 2.31
Depletion of B cells in murine lupus: efficacy and resistance. J Immunol (2007) 2.25
Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci U S A (2008) 2.18
Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol (2010) 2.18
The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest (2011) 2.14
T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity (2008) 2.03
Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev (2008) 1.90
The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev (1999) 1.88
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice. Eur J Immunol (2011) 1.73
Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol (2011) 1.73
Type I IFN protects against murine lupus. J Immunol (2004) 1.71
Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity (2010) 1.70
Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res (2011) 1.69
B-cell self-tolerance in humans. Adv Immunol (2007) 1.65
Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest (2003) 1.63
Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum (2001) 1.61
Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet (2011) 1.57
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2010) 1.55
Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev (2009) 1.53
FcR-bearing myeloid cells are responsible for triggering murine lupus nephritis. J Immunol (2006) 1.42
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis (2011) 1.38
Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.37
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis (2011) 1.37
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
BAFF and selection of autoreactive B cells. Trends Immunol (2011) 1.36
Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol (2005) 1.35
Extrafollicular B cell activation by marginal zone dendritic cells drives T cell-dependent antibody responses. J Exp Med (2012) 1.23
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum (2012) 1.21
Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol (2012) 1.19
Recent findings on genetics of systemic autoimmune diseases. Curr Opin Immunol (2010) 1.19
B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther (2003) 1.15
Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J Immunol (2010) 1.13
Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum (2010) 1.13
The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol (2012) 1.12
Dissecting the immune cell mayhem that drives lupus pathogenesis. Sci Transl Med (2011) 1.11
The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum Immunol (2002) 1.06
Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev (2008) 1.02
Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus. Int Arch Allergy Immunol (2010) 1.00
Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol (1998) 1.00
Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci (2012) 0.93
Active immunisation of human interferon α transgenic mice with a human interferon α Kinoid induces antibodies that neutralise interferon α in sera from patients with systemic lupus erythematosus. Ann Rheum Dis (2011) 0.93
Plasma cells in systemic lupus erythematosus: the long and short of it all. Eur J Immunol (2011) 0.92
A Toll for lupus. Lupus (2005) 0.92
An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus. J Immunol (2011) 0.88
Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren's syndrome. Curr Opin Rheumatol (2012) 0.81
Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science (2009) 9.22
ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med (2008) 3.39
In vivo regulation of Bcl6 and T follicular helper cell development. J Immunol (2010) 2.63
Differential expression of Ly6C and T-bet distinguish effector and memory Th1 CD4(+) cell properties during viral infection. Immunity (2011) 2.54
Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. Arthritis Rheumatol (2015) 2.29
IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J Immunol (2003) 2.03
Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med (2003) 1.99
Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.93
Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 1.84
Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol (2004) 1.80
IL-10 regulates murine lupus. J Immunol (2002) 1.70
Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol (2009) 1.61
Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol (2004) 1.45
T-Bet expression and failure of GATA-3 cross-regulation lead to default production of IFN-gamma by gammadelta T cells. J Immunol (2002) 1.34
Age-dependent requirement for gammadelta T cells in the primary but not secondary protective immune response against an intestinal parasite. J Exp Med (2003) 1.07
T cells that promote B-Cell maturation in systemic autoimmunity. Immunol Rev (2012) 1.06
IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice. J Immunol (2012) 1.02
Resistance to development of collagen-induced arthritis in C57BL/6 mice is due to a defect in secondary, but not in primary, immune response. J Clin Immunol (2004) 1.00
B cells in T follicular helper cell development and function: separable roles in delivery of ICOS ligand and antigen. J Immunol (2014) 0.99
Epigenetic and transcriptional programs lead to default IFN-gamma production by gammadelta T cells. J Immunol (2007) 0.98
ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus. J Immunol (2009) 0.98
Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest (2013) 0.96
Editing antigen presentation: antigen transfer between human B lymphocytes and macrophages mediated by class A scavenger receptors. J Immunol (2008) 0.95
Naive CD4+ T cells from lupus-prone Fas-intact MRL mice display TCR-mediated hyperproliferation due to intrinsic threshold defects in activation. J Immunol (2005) 0.94
Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol (2004) 0.91
Barrier immunity and IL-17. Semin Immunol (2009) 0.88
Emerging from the shadows: follicular helper T cells in autoimmunity. Arthritis Rheum (2010) 0.83
Regulation of T cell-dependent autoantibody production by a gammadelta T cell line derived from lupus-prone mice. Cell Immunol (2002) 0.82
IL-7Rαlow memory CD8+ T cells are significantly elevated in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2012) 0.81
Caspase-activated DNase is required for maintenance of tolerance to lupus nuclear autoantigens. Arthritis Rheum (2011) 0.80
Development of a nanoparticulate formulation of retinoic acid that suppresses Th17 cells and upregulates regulatory T cells. Self Nonself (2010) 0.79
The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials (2013) 0.79
Oxazolone and diclofenac-induced popliteal lymph node assay reactions are attenuated in mice orally pretreated with the respective compound: potential role for the induction of regulatory mechanisms following enteric administration. Toxicol Appl Pharmacol (2003) 0.78
Activation of naive CD4+ T cells in vivo by a self-peptide mimic: mechanism of tolerance maintenance and preservation of immunity. J Immunol (2004) 0.77
Competing for help: new insights into the function of follicular helper T cells. Immunol Cell Biol (2009) 0.75
Roquin paralogs add a new dimension to ICOS regulation. Immunity (2013) 0.75